Literature DB >> 11557617

Orexin depolarizes rat hypothalamic paraventricular nucleus neurons.

T Shirasaka1, S Miyahara, T Kunitake, Q H Jin, K Kato, M Takasaki, H Kannan.   

Abstract

Orexins, also called hypocretins, are newly discovered hypothalamic peptides that are thought to be involved in various physiological functions. In spite of the fact that orexin receptors, especially orexin receptor 2, are abundant in the hypothalamic paraventricular nucleus (PVN), the effects of orexins on PVN neurons remain unknown. Using a whole cell patch-clamp recording technique, we investigated the effects of orexin-B on PVN neurons of rat brain slices. Bath application of orexin-B (0.01-1.0 microM) depolarized 80.8% of type 1 (n = 26) and 79.2% of type 2 neurons tested (n = 24) in the PVN in a concentration-dependent manner. The effects of orexin-B persisted in the presence of TTX (1 microM), indicating that these depolarizing effects were generated postsynaptically. Addition of Cd(2+) (1 mM) to artificial cerebrospinal fluid containing TTX (1 microM) significantly reduced the depolarizing effect in type 2 neurons. These results suggest that orexin-B has excitatory effects on the PVN neurons mediated via a depolarization of the membrane potential.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11557617     DOI: 10.1152/ajpregu.2001.281.4.R1114

Source DB:  PubMed          Journal:  Am J Physiol Regul Integr Comp Physiol        ISSN: 0363-6119            Impact factor:   3.619


  19 in total

1.  Upregulation of orexin receptor in paraventricular nucleus promotes sympathetic outflow in obese Zucker rats.

Authors:  Jing-Jing Zhou; Fang Yuan; Yi Zhang; De-Pei Li
Journal:  Neuropharmacology       Date:  2015-08-12       Impact factor: 5.250

2.  Optogenetic identification of hypothalamic orexin neuron projections to paraventricular spinally projecting neurons.

Authors:  Olga Dergacheva; Akihiro Yamanaka; Alan R Schwartz; Vsevolod Y Polotsky; David Mendelowitz
Journal:  Am J Physiol Heart Circ Physiol       Date:  2017-02-03       Impact factor: 4.733

Review 3.  The paraventricular nucleus of the hypothalamus - a potential target for integrative treatment of autonomic dysfunction.

Authors:  Alastair V Ferguson; Kevin J Latchford; Willis K Samson
Journal:  Expert Opin Ther Targets       Date:  2008-06       Impact factor: 6.902

4.  Cellular mechanisms of orexin actions on paraventricular nucleus neurones in rat hypothalamus.

Authors:  Matthew J Follwell; Alastair V Ferguson
Journal:  J Physiol       Date:  2002-12-15       Impact factor: 5.182

5.  Orexin receptor subtype activation and locomotor behaviour in the rat.

Authors:  W K Samson; S L Bagley; A V Ferguson; M M White
Journal:  Acta Physiol (Oxf)       Date:  2009-11-04       Impact factor: 6.311

Review 6.  Implicating the potential role of orexin in hypertension.

Authors:  Monika Rani; Raghuvansh Kumar; Pawan Krishan
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2017-05-16       Impact factor: 3.000

7.  Increased activity of the orexin system in the paraventricular nucleus contributes to salt-sensitive hypertension.

Authors:  Michael J Huber; Yuanyuan Fan; Enshe Jiang; Fengli Zhu; Robert A Larson; Jianqun Yan; Ningjun Li; Qing-Hui Chen; Zhiying Shan
Journal:  Am J Physiol Heart Circ Physiol       Date:  2017-06-30       Impact factor: 4.733

Review 8.  The Orexin System and Hypertension.

Authors:  Michael J Huber; Qing-Hui Chen; Zhiying Shan
Journal:  Cell Mol Neurobiol       Date:  2017-03-27       Impact factor: 5.046

9.  Hypocretins regulate the anxiogenic-like effects of nicotine and induce reinstatement of nicotine-seeking behavior.

Authors:  Ainhoa Plaza-Zabala; Elena Martín-García; Luis de Lecea; Rafael Maldonado; Fernando Berrendero
Journal:  J Neurosci       Date:  2010-02-10       Impact factor: 6.167

10.  Yohimbine depresses excitatory transmission in BNST and impairs extinction of cocaine place preference through orexin-dependent, norepinephrine-independent processes.

Authors:  Kelly L Conrad; Adeola R Davis; Yuval Silberman; Douglas J Sheffler; Angela D Shields; Sam A Saleh; Namita Sen; Heinrich J G Matthies; Jonathan A Javitch; Craig W Lindsley; Danny G Winder
Journal:  Neuropsychopharmacology       Date:  2012-05-23       Impact factor: 7.853

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.